“Koteya Bio” completed the A+ round of financing of over 100 million yuan

On November 7th, Ketai Biotechnology Co., Ltd. (abbreviation: Ketai Bio) announced the completion of the A+ round of financing of over 100 million yuan, invested by Eight Roads Capital and Sequoia China, and old shareholders Source Code Capital and Food Core Capital. Follow the vote. Among them, the source code is the lead investor of the company’s A round of financing. This round of financing will be used for pipeline research and development, talent team expansion, and accelerated construction and operation of production facilities. Previously, Ketai Bio completed a series A financing of over 100 million yuan in the first half of 2022. This financing is also the third round of financing completed within 1 year of Ketai Bio.

Ketea Bio was established in September 2021. Kotea is a synthetic biology company dedicated to creating pure, safe, and sustainable bio-based products. The company has a global vision and resource capabilities. The R&D center is located in Shanghai, China. At the same time, R&D and business divisions will be established in Japan and the United States in the near future. The company applies cutting-edge synthetic biology technology to provide natural, green and sustainable innovative raw material products for nutrition, personal care, medicine and other markets through high-end bio-manufacturing, thereby helping the current society to get rid of its dependence on oil, and solving problems including environmental pollution, carbon global issues such as emissions and climate change.

Kotea Bio is one of the few synthetic biology companies in the world with both R&D capabilities and production delivery capabilities. The founder and CEO, Dr. Zhao Lishan, once served as the vice president of R&D and the president of China at the American synthetic biology pioneer Amyris. The founding team headed by Dr. Zhao has more than 40 years of experience in synthetic biology R&D and product development at home and abroad. Since the establishment of the company one year ago, it has formed a team of 30 people from leading domestic and foreign synthetic biology companies such as Amyris, Evonik, and Meihua Biology, and has initially built a world-class R&D platform. Its own product pipeline is also rapidly advancing. . Taking full advantage of the team’s global vision and resources, the company has cooperated with a number of overseas companies in depth; by grafting overseas advanced R&D technologies and the advantages of China’s local bio-manufacturing supply chain, and superimposing its own advanced synthetic biology platform R&D capabilities to achieve Products are delivered “end-to-end” in production.